An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations

Condition: Urothelial Cancer | Last Updated: August 2019 | Status: Recruiting

View Full Study